The current management of HBV drug resistance
- 1 December 2005
- journal article
- review article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 34, S143-S146
- https://doi.org/10.1016/s1386-6532(05)80025-3
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Switching to adefovir monotherapy after emergence of lamivudine‐resistant mutations in patients with liver cirrhosisJournal of Viral Hepatitis, 2006
- Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis BJournal of Hepatology, 2005
- 382 In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymeraseJournal of Hepatology, 2004
- The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine—5 years observationHepatology Research, 2003
- Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapyThe Esophagus, 2002
- The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis BHepatology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Lamivudine resistance inimmunocompetent chronic hepatitis BJournal of Hepatology, 1997
- Antiviral Activity Spectrum and Target of Action of Different Classes of Nucleoside AnaloguesNucleosides and Nucleotides, 1994